Disease · MONDO_0020678

sensorineural hearing loss disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. sensorineural hearing loss disorder. Diseases, record MONDO_0020678. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020678

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: sensorineural hearing loss disorder; Open Targets
Open Targets ID: MONDO_0020678; Open Targets
Other names: Hearing Loss, Central, Hearing loss, sensorineural, High Frequency Hearing Loss, High frequency deafness, Perceptive deafness [diagnos], Perceptive hearing loss, Perceptive hearing loss or deafness, SNHL, Sensorineural hearing impairment, Sensory hearing loss, central hearing loss, sensorineural deafness, sensorineural hearing loss; Open Targets
Disease Ontology: DOID:10003; Disease Ontology
NCI Thesaurus: C26739; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 8 of its 17 drugs, from ClinicalTrials.gov; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	4	4	3	Drugs and targets
VALGANCICLOVIR	CHEMBL1201314	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
GLYCERIN	CHEMBL692	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PIOGLITAZONE HYDROCHLORIDE	CHEMBL1715	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
BRIMAPITIDE, C-TERMINAL ACID	CHEMBL4297348	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LADUVIGLUSIB	CHEMBL412142	Small molecule	Phase 1/2	ClinicalTrials.gov	2	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets14

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
ALDH5A1	Succinate-semialdehyde dehydrogenase, mitochondrial	1	Succinate semialdehyde dehydrogenase inhibitor	Phase 1/2	https://conductscience.org/library/genes/7915	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 3	https://conductscience.org/library/genes/1719	Drugs and targets
FAAH	Fatty-acid amide hydrolase 1	1	Anandamide amidohydrolase inhibitor	Phase 3	https://conductscience.org/library/genes/2166	Drugs and targets
GRIA1	Glutamate receptor ionotropic AMPA	1	Glutamate receptor ionotropic AMPA positive allosteric modulator	Phase 1	https://conductscience.org/library/genes/2890	Drugs and targets
GRIA2	Glutamate receptor ionotropic AMPA	1	Glutamate receptor ionotropic AMPA positive allosteric modulator	Phase 1	https://conductscience.org/library/genes/2891	Drugs and targets
GRIA3	Glutamate receptor ionotropic AMPA	1	Glutamate receptor ionotropic AMPA positive allosteric modulator	Phase 1	https://conductscience.org/library/genes/2892	Drugs and targets
GRIA4	Glutamate receptor ionotropic AMPA	1	Glutamate receptor ionotropic AMPA positive allosteric modulator	Phase 1	https://conductscience.org/library/genes/2893	Drugs and targets
IL1R1	Interleukin-1 receptor type 1	1	Interleukin-1 receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/3554	Drugs and targets
MAPK10	Mitogen-activated protein kinase 10	1	c-Jun N-terminal kinase 3 inhibitor	Phase 2	https://conductscience.org/library/genes/5602	Drugs and targets

1 to 10 of 14

See all 14 targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01649869	Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss	Phase 2	54	2021-06-02	Cytomegalovirus Infection	VALGANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT03616223	FX-322 in Sensorineural Hearing Loss	Phase 1/2	23	2022-11-14	Sensorineural Hearing Loss	LADUVIGLUSIB, VALPROATE SODIUM	Its record names the disease	ClinicalTrials.gov
NCT02414152	Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss	Phase 1/2	2	2016-12-05	Hearing Loss, Sudden	ANAKINRA	Its record names the disease	ClinicalTrials.gov
NCT00619203	Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis	Phase 3	466		Bacterial Meningitis	ACETAMINOPHEN, GLYCERIN	Its record names the disease	ClinicalTrials.gov
NCT00802425	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss	Phase 2	210		Hearing Loss	BRIMAPITIDE, C-TERMINAL ACID	Its record names the disease	ClinicalTrials.gov
NCT07283562	Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo	Not applicable	100		Sensorineural Hearing Loss, Vertigo	DEXTRAN 40, GASTRODIN	Its record names the disease	ClinicalTrials.gov
NCT00416143	Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss	Phase 2/3	60		Sudden Loss of Hearing	PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT06598059	Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array	Not applicable	56		Hearing Loss	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT01518920	A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss	Phase 1	44		Hearing Loss, Sensorineural	PESAMPATOR	Its record names the disease	ClinicalTrials.gov
NCT02603081	Study to Evaluate SPI-1005 in Adults With Meniere's Disease	Phase 1/2	40		Meniere's Disease	EBSELEN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Active vs Placebo: deaths from any cause	0 of 17	0 of 18	35	NCT01649869	Trial comparisons
Active vs Placebo: serious adverse events	1 of 17	0 of 18	35	NCT01649869	Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25133431	RESULT	1	PubMed
38415855	DERIVED	1	PubMed
38309519	DERIVED	1	PubMed
32483557	DERIVED	1	PubMed
25997115	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0020678

GET https://conductscience.org/api/diseases/v1/MONDO_0020678/drugs

API reference For AI assistants